Tumor-infiltrating Lymphocytes (TIL)

BIOLOGICAL3 trials

Conditions

AdenocarcinomasAdenosquamous CarcinomaAdvanced NSCLCCancer of Gastrointestinal TractCancer, GastrointestinalColo-rectal CancerColon CancerEsophageal Cancer

Phase 1

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

CompletedNCT03215810

H. Lee Moffitt Cancer Center and Research InstituteAdenocarcinomas, Adenosquamous Carcinoma, Advanced NSCLC +3

Start: 2017-10-11End: 2023-06-09Updated: 2023-07-24

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

CompletedNCT04426669

Intima Bioscience, Inc.Cancer, Gastrointestinal, Cancer of Gastrointestinal Tract, Colon Cancer +8

Start: 2020-05-15End: 2026-01-22Updated: 2026-02-23

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

RecruitingNCT05681780

H. Lee Moffitt Cancer Center and Research InstituteNon Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Start: 2023-03-10End: 2027-12-01Target: 20Updated: 2026-09-16

Journal of Cancer and Tumor International2025-08-23

Clinical manufacture of CRISPR/Cas9-based cytokine-induced SH2 protein knock-out tumor-infiltrating lymphocytes for gastrointestinal cancers.

2025-06-21

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial.

2025-04-2918 citations

Abstract CT269: First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint <i>CISH</i> is inhibited

Cancer Research2025-04-251 citations

CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

Journal for ImmunoTherapy of Cancer2025-04-016 citations

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC.

2024-05-161 citations

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

Journal for ImmunoTherapy of Cancer2024-02-0142 citations

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for ImmunoTherapy of Cancer2021-10-0161 citations

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.

2021-08-12321 citations

333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program

Regular and Young Investigator Award Abstracts2020-11-0112 citations

280 Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients

Regular and Young Investigator Award Abstracts2020-11-011 citations

Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial

Cancer Research2020-08-1525 citations

Tumor-infiltrating Lymphocytes (TIL)

Sponsors

Conditions

Phase 1

Related Papers